Quarantini Lucas C, Bressan Rodrigo A, Galvão Amanda, Batista-Neves Susana, Paraná Raymundo, Miranda-Scippa Angela
University Hospital, Federal University of Bahia School of Medicine, Salvador-Bahia, Brazil.
Liver Int. 2007 Oct;27(8):1098-102. doi: 10.1111/j.1478-3231.2007.01532.x.
Evaluate the incidence of mental disorders using pegylated interferon plus ribavirin retreatment in nonresponder hepatitis C virus-infected patients.
The Mini-International Neuropsychiatric Interview (MINI) was used to evaluate 30 hepatitis C virus-infected interferon-nonresponder patients at baseline and following 4, 12 and 24 weeks of pegylated interferon retreatment.
During the pegylated interferon/ribavirin retreatment, 5(16.6%) patients developed psychiatric side effects: 3(10%) were diagnosed with major depressive disorder, 1(3.3%) had a brief psychotic disorder and 1(3.3%) presented with panic attacks.
This is the first prospective study evaluating the incidence of neuropsychiatric side effects during interferon retreatment of hepatitis C virus-infected patients, suggesting that the risk of acquiring serious psychiatric symptoms during retreatment with interferon-alpha (IFN-alpha) may not be higher than during the first antiviral therapy. This finding challenges the hypothesis that during a second treatment with IFN-alpha, patients with hepatitis C may be at greater risk for neuropsychiatric side effects than naïve patients.
评估聚乙二醇干扰素联合利巴韦林再治疗对丙型肝炎病毒感染的无应答患者精神障碍发病率的影响。
采用迷你国际神经精神访谈量表(MINI)对30例丙型肝炎病毒感染的干扰素无应答患者在基线时以及聚乙二醇干扰素再治疗4周、12周和24周后进行评估。
在聚乙二醇干扰素/利巴韦林再治疗期间,5例(16.6%)患者出现精神副作用:3例(10%)被诊断为重度抑郁症,1例(3.3%)患有短暂性精神病性障碍,1例(3.3%)出现惊恐发作。
这是第一项评估丙型肝炎病毒感染患者干扰素再治疗期间神经精神副作用发生率的前瞻性研究,表明用α干扰素(IFN-α)再治疗期间出现严重精神症状的风险可能不高于首次抗病毒治疗期间。这一发现对以下假设提出了挑战,即丙型肝炎患者在第二次接受IFN-α治疗时,出现神经精神副作用的风险可能高于初治患者。